Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 16, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies.

Yang Yang1, Xia Bi1, Mia Gergis2

  • 1Tomas Jefferson University Sidney Kimmel Medical College, United States.

Hematology/Oncology and Stem Cell Therapy
|December 20, 2022
PubMed
Summary

Allogeneic chimeric antigen receptor (CAR) T cell therapy offers a scalable alternative to autologous CAR T therapy for blood cancers. While challenges remain, early results for hematologic malignancies are promising.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies - A Prospective Trial.

Transplantation and cellular therapy·2026
Same author

Bidirectional regulatory effects of frequency-dependent splenic apex electrical stimulation on peripheral immune suppression and central neural repair after spinal cord injury.

Neural regeneration research·2026
Same author

Absent Cyclin D1 Expression in Myeloid Sarcomas Distinguishes From Malignant Histiocytic Neoplasms: When Morphologic Ambiguity is Deceptive.

The American journal of surgical pathology·2026
Same authorSame journal

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

Hematology/oncology and stem cell therapy·2026
Same author

Synergistic Neuroprotection of Fe<sub>3</sub>O<sub>4</sub> Nanoparticles Combined with Intermittent Theta Burst Stimulation in Ischemic Stroke via Nrf2-Mediated Ferroptosis Regulation.

International journal of nanomedicine·2026
Same author

Targeting the microbiota-gut-brain axis in post-stroke insomnia: a phase-dependent therapeutic framework.

Frontiers in neuroscience·2026

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Autologous chimeric antigen receptor (CAR) T cell therapy is FDA-approved for various B-cell malignancies but faces challenges like high cost and long production times.
  • Allogeneic CAR T cell therapy, while promising, encounters hurdles such as graft-versus-host disease and potential cell rejection.

Purpose of the Study:

  • To compare the advantages and disadvantages of autologous and allogeneic CAR T cell therapies for hematologic malignancies.
  • To review the latest clinical data and discuss the scalability of allogeneic CAR T cell approaches.

Main Methods:

  • Review of existing literature and clinical trial data on autologous and allogeneic CAR T cell therapies.
  • Discussion of strategies to overcome limitations in allogeneic CAR T cell therapy, including HLA and T cell receptor modification.

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

719

Related Experiment Videos

Last Updated: Aug 16, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

719

Main Results:

  • Autologous CAR T therapy is established but costly and complex.
  • Early clinical trials of allogeneic CAR T therapy for B-cell leukemias and lymphomas show promising results.
  • Ongoing large-scale clinical trials are evaluating the efficacy and safety of allogeneic CAR T approaches.

Conclusions:

  • Allogeneic CAR T cell therapy presents a potentially more scalable and accessible option for treating hematologic malignancies.
  • Further research and large clinical trials are crucial to validate the safety, efficacy, and long-term outcomes of allogeneic CAR T cell therapy.